Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: Metabolism. 2008 Jan;57(1):77–83. doi: 10.1016/j.metabol.2007.08.009

Table 5.

Quartile analysis for evaluating the relative risk (RR) for recurrent CVD events (%) in the gemfibrozil arm of VA-HIT.

Quartile-1 Quartile-2 Quartile-3 Quartile-4 RR (95% CI) p-value* Trend-Test ** P=
Percent (%) new CVD events
Preβ-1† 14.9 22.2 24.1 27.9 1.95 (1.22,3.11) 0.005 0.003
Preβ-2 23.4 26.6 24.2 14.9 0.55 (0.33,0.89) 0.02 0.04
α-1 24.9 25.5 21.3 17.5 0.70 (0.44,1.11) 0.13 0.05
α-2 29.1 27.7 16.5 15.9 0.57 (0.36,0.90) 0.02 0.0002
α-3 19.1 23.4 24.5 22.2 1.03 (0.66,1.63) 0.89 0.43
preα-1 24.9 20.7 26.5 17.0 0.69 (0.37,1.09) 0.11 0.19
preα-2 28.0 20.0 24.6 16.5 0.58 (0.37,0.92) 0.02 0.03
preα-3 23.8 27.7 18.0 19.7 0.80 (0.52,1.25) 0.33 0.10

N=754 including 168 subjects with recurrent CVD events (stroke, non-fatal MI or CHD death).

*

P-values for RR were calculated by comparing data in quartile 4 to data in quartile 1. Data were adjusted for age, smoking, hypertension, BMI, and diabetes.

**

Cochran-Armitage trend test.

†

The trend between particle concentrations and recurrent CVD events is positive.